RECURSION PHARMACEUTICALS, INC. Finance Lease, Right-of-Use Asset, Amortization
RECURSION PHARMACEUTICALS, INC. (RXRX) reported Finance Lease, Right-of-Use Asset, Amortization of $6.06 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:FinanceLeaseRightOfUseAssetAmortization · last filed 2026-02-25
- RECURSION PHARMACEUTICALS, INC. finance lease, right-of-use asset, amortization for the quarter ending 2024-12-31 was $1.60M.
- RECURSION PHARMACEUTICALS, INC. finance lease, right-of-use asset, amortization for the quarter ending 2024-09-30 was $1.46M.
- RECURSION PHARMACEUTICALS, INC. finance lease, right-of-use asset, amortization for the quarter ending 2024-06-30 was $985.00K.
- RECURSION PHARMACEUTICALS, INC. finance lease, right-of-use asset, amortization for the quarter ending 2023-12-31 was $0.00.
- RECURSION PHARMACEUTICALS, INC. finance lease, right-of-use asset, amortization for fiscal 2025 was $6.06M, a 50.00% increase from fiscal 2024.
- RECURSION PHARMACEUTICALS, INC. finance lease, right-of-use asset, amortization for fiscal 2024 was $4.04M.
- RECURSION PHARMACEUTICALS, INC. finance lease, right-of-use asset, amortization for fiscal 2023 was $0.00.
- RECURSION PHARMACEUTICALS, INC. finance lease, right-of-use asset, amortization for fiscal 2022 was $0.00.
| Period end | Finance Lease, Right-of-Use Asset, Amortization 3 month | Finance Lease, Right-of-Use Asset, Amortization 6 month | Finance Lease, Right-of-Use Asset, Amortization 9 month | Finance Lease, Right-of-Use Asset, Amortization 12 month |
|---|---|---|---|---|
| 2025-12-31 | $6.06M 10-K · filed 2026-02-25 | |||
| 2024-12-31 | $1.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $3.06M derived: sum of 2 quarters · filed 2026-02-25 | $4.04M derived: sum of 3 quarters · filed 2026-02-25 | $4.04M 10-K · filed 2026-02-25 |
| 2024-09-30 | $1.46M 10-Q · filed 2024-11-06 | $2.44M derived: sum of 2 quarters · filed 2024-11-06 | $2.44M 10-Q · filed 2024-11-06 | |
| 2024-06-30 | $985.00K 10-Q · filed 2024-08-08 | $985.00K 10-Q · filed 2024-08-08 | ||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $0.00 derived: sum of 2 quarters · filed 2026-02-25 | $0.00 derived: sum of 3 quarters · filed 2026-02-25 | $0.00 10-K · filed 2026-02-25 |
| 2023-09-30 | $0.00 10-Q · filed 2024-11-06 | $0.00 derived: sum of 2 quarters · filed 2024-11-06 | $0.00 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $0.00 10-Q · filed 2024-08-08 | $0.00 10-Q · filed 2024-08-08 | ||
| 2022-12-31 | $0.00 10-K · filed 2025-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |